Skip to main content
OpenTrials

Clinical trial condition

Endometrial Clear Cell Adenocarcinoma

Explore clinical trials studying Endometrial Clear Cell Adenocarcinoma. Study availability and eligibility vary by location and protocol.

26 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Endometrial Clear Cell Adenocarcinoma trial results

Recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225

Conditions
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
View all 409 locations
View Trial Details
Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

NCT05112601

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University Cancer and Blood Center LLC Athens, Georgia, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • Saint Alphonsus Cancer Care Center-Boise Boise, Idaho, United States
View all 137 locations
View Trial Details
Recruiting

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

NCT03422198

Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, +6 more
Locations
  • Stanford Cancer Center Palo Alto, California, United States
  • Loyola University Medical Center Maywood, Illinois, United States
  • MD Anderson Houston, Texas, United States
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
View Trial Details
Completed

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

NCT01935934

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
View all 19 locations
View Trial Details
Completed

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02020707

Conditions
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, +45 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details
Completed

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

NCT02501954

Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, +3 more
Locations
  • Greater Baltimore Medical Center Baltimore, Maryland, United States
  • Munson Health Care Traverse City, Michigan, United States
  • Atlantic Health Morristown, New Jersey, United States
  • Women's Cancer Care Associates, LLC Albany, New York, United States
View Trial Details
Completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

NCT01307631

Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, +2 more
Locations
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Massachusetts General Hospital Charlestown, Massachusetts, United States
View Trial Details
Completed

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01935973

Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, +3 more
Locations
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View all 22 locations
View Trial Details
Completed

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01132820

Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, +2 more
Locations
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • Palo Alto Medical Foundation-Gynecologic Oncology Mountain View, California, United States
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
View all 87 locations
View Trial Details

Related conditions